AVITA Medical, Inc. (NASDAQ: RCEL) reported Q2 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.68 million.

GUIDANCE:

AVITA Medical, Inc. sees Q3 2024 revenue of $19-20 million, versus the consensus of $21.563 million, reflecting growth of approximately 40% to 48% over the same period in 2023
Commercial revenue for the full-year 2024 is now expected to be in the range of $68.0 to $70.0 million, versus the consensus of $75.435 million, reflecting growth of approximately 37% to 41% over the full-year 2023
Expect to achieve previously given guidance of cashflow break even and GAAP profitability no later than the end of the third quarter of 2025

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.